Melatonin and cancer - a review of the literature

Detalhes bibliográficos
Autor(a) principal: Sousa Neto, Júlio Anselmo
Data de Publicação: 2005
Outros Autores: Scaldaferri, Paulo Mallard
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/1997
Resumo: This paper is a literature review of the three last decades about the role of melatonin (MEL) in the pathogenesis and treatment of cancer. MEL's major mechanisms of action involve immunologic regulation, biochemical and metabolic effects. In vitro and in vivo studies are described, including some in humans with advanced or metastatic cancer (breast, prostatic, pulmonary, gastric, hepatic, ovarian and intestinal tumors). MEL has two particularly important actions: oncostatic and protective against the main adverse effects of chemotheraphy (myelodisplastic, neurotoxic and hematologic). MEL was first used as a new type of oncologic therapy, the immunotherapy, in the 1990s to treat patients with non-small cell lung cancer.
id INCA-1_ff4d4436aa3814a1f1dc63557ce417ba
oai_identifier_str oai:rbc.inca.gov.br:article/1997
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Melatonin and cancer - a review of the literatureMelatonina e câncer - revisão da literaturaMelatoninaNeoplasiasImunoterapiaGlândula pinealMelatoninNeoplasmsImmunotherapyPineal glandThis paper is a literature review of the three last decades about the role of melatonin (MEL) in the pathogenesis and treatment of cancer. MEL's major mechanisms of action involve immunologic regulation, biochemical and metabolic effects. In vitro and in vivo studies are described, including some in humans with advanced or metastatic cancer (breast, prostatic, pulmonary, gastric, hepatic, ovarian and intestinal tumors). MEL has two particularly important actions: oncostatic and protective against the main adverse effects of chemotheraphy (myelodisplastic, neurotoxic and hematologic). MEL was first used as a new type of oncologic therapy, the immunotherapy, in the 1990s to treat patients with non-small cell lung cancer.Este trabalho apresenta uma revisão da literatura das três últimas décadas sobre o papel da melatonina (MEL) na etiopatogenia e no tratamento do câncer. Os principais mecanismos de ação da MEL envolvem a regulação imunológica, efeitos bioquímicos e metabólicos. São relatados estudos in vitro e in vivo, inclusive em humanos com neoplasias malignas avançadas e/ou metastáticas, como tumores de mama, próstata, pulmonar, gástrico, hepático, ovariano e de intestino. Duas ações benéficas da MEL no tratamento do câncer são aparentemente importantes: a oncostática e a protetora contra os efeitos adversos da quimioterapia (mielossupressores, neurotóxicos e hematológicos). A MEL também passou a ser utilizada em uma nova modalidade de terapia oncológica, a imunoterapia, na década de 1990 para tratar pacientes com câncer de pulmão de células não-pequenas.INCA2005-03-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisão de literaturaapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/199710.32635/2176-9745.RBC.2005v51n1.1997Revista Brasileira de Cancerologia; Vol. 51 No. 1 (2005): Jan./Feb./Mar.; 49-58Revista Brasileira de Cancerologia; Vol. 51 Núm. 1 (2005): ene./feb./mar.; 49-58Revista Brasileira de Cancerologia; v. 51 n. 1 (2005): jan./fev./mar.; 49-582176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/1997/1220Sousa Neto, Júlio AnselmoScaldaferri, Paulo Mallardinfo:eu-repo/semantics/openAccess2021-11-29T20:30:56Zoai:rbc.inca.gov.br:article/1997Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:30:56Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Melatonin and cancer - a review of the literature
Melatonina e câncer - revisão da literatura
title Melatonin and cancer - a review of the literature
spellingShingle Melatonin and cancer - a review of the literature
Sousa Neto, Júlio Anselmo
Melatonina
Neoplasias
Imunoterapia
Glândula pineal
Melatonin
Neoplasms
Immunotherapy
Pineal gland
title_short Melatonin and cancer - a review of the literature
title_full Melatonin and cancer - a review of the literature
title_fullStr Melatonin and cancer - a review of the literature
title_full_unstemmed Melatonin and cancer - a review of the literature
title_sort Melatonin and cancer - a review of the literature
author Sousa Neto, Júlio Anselmo
author_facet Sousa Neto, Júlio Anselmo
Scaldaferri, Paulo Mallard
author_role author
author2 Scaldaferri, Paulo Mallard
author2_role author
dc.contributor.author.fl_str_mv Sousa Neto, Júlio Anselmo
Scaldaferri, Paulo Mallard
dc.subject.por.fl_str_mv Melatonina
Neoplasias
Imunoterapia
Glândula pineal
Melatonin
Neoplasms
Immunotherapy
Pineal gland
topic Melatonina
Neoplasias
Imunoterapia
Glândula pineal
Melatonin
Neoplasms
Immunotherapy
Pineal gland
description This paper is a literature review of the three last decades about the role of melatonin (MEL) in the pathogenesis and treatment of cancer. MEL's major mechanisms of action involve immunologic regulation, biochemical and metabolic effects. In vitro and in vivo studies are described, including some in humans with advanced or metastatic cancer (breast, prostatic, pulmonary, gastric, hepatic, ovarian and intestinal tumors). MEL has two particularly important actions: oncostatic and protective against the main adverse effects of chemotheraphy (myelodisplastic, neurotoxic and hematologic). MEL was first used as a new type of oncologic therapy, the immunotherapy, in the 1990s to treat patients with non-small cell lung cancer.
publishDate 2005
dc.date.none.fl_str_mv 2005-03-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Revisão de literatura
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/1997
10.32635/2176-9745.RBC.2005v51n1.1997
url https://rbc.inca.gov.br/index.php/revista/article/view/1997
identifier_str_mv 10.32635/2176-9745.RBC.2005v51n1.1997
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/1997/1220
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 51 No. 1 (2005): Jan./Feb./Mar.; 49-58
Revista Brasileira de Cancerologia; Vol. 51 Núm. 1 (2005): ene./feb./mar.; 49-58
Revista Brasileira de Cancerologia; v. 51 n. 1 (2005): jan./fev./mar.; 49-58
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042248883372032

Registros relacionados